Inhalable Liposomes of Fasudil-a Novel Rho-Kinase Inhibitor for the Treatment of PAH

摘要

This study tests the hypothesis that encapsulating fasudil, a novel Rho-kinase inhibitor, in inhalable liposomal formulations increases the half-life and circulation time and provides controlled release of the drugs following pulmonary administration. The results showed that liposomal fasudil produced an increase in the half-life of the drug (4 hrs) after pulmonary administration.